Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC) and in a preclinical model on colon cancer, will be presented at Digestive Disease Week (DDW) as part of scientific exchange, taking place May 18-21, 2024, in Washington D.C., U.S.
Market Closed -
Other stock markets
|
After market 15:07:01 | |||
12.58 EUR | +2.78% | 12.5 | -0.64% |
05-20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
05-08 | Abivax: four abstracts to be presented on obefazimod | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.11% | 835M | |
+42.29% | 58.06B | |
-6.05% | 40.53B | |
+37.52% | 38.99B | |
+14.15% | 26.7B | |
-12.56% | 26.56B | |
-21.62% | 18.98B | |
-0.95% | 12.17B | |
+23.88% | 12B | |
+24.72% | 11.92B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024